These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24161214)

  • 1. IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand.
    Guerra-Menéndez L; Sádaba MC; Puche JE; Lavandera JL; de Castro LF; de Gortázar AR; Castilla-Cortázar I
    J Transl Med; 2013 Oct; 11():271. PubMed ID: 24161214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
    Dela Cruz A; Grynpas MD; Mitchell J
    Am J Physiol Endocrinol Metab; 2016 May; 310(10):E811-20. PubMed ID: 27006198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin like growth factor-I: a critical mediator of the skeletal response to parathyroid hormone.
    Bikle DD; Wang Y
    Curr Mol Pharmacol; 2012 Jun; 5(2):135-42. PubMed ID: 21787292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of osteoblastic metalloproteinases in mice prevents bone loss induced by oestrogen deficiency.
    Schiltz C; Marty C; de Vernejoul MC; Geoffroy V
    J Cell Biochem; 2008 Aug; 104(5):1803-17. PubMed ID: 18384129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
    Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
    Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage.
    Geoffroy V; Kneissel M; Fournier B; Boyde A; Matthias P
    Mol Cell Biol; 2002 Sep; 22(17):6222-33. PubMed ID: 12167715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Chen Y; Sun LH; Zhang LZ; Xu MY; Chen JL
    Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo.
    Rubin J; Ackert-Bicknell CL; Zhu L; Fan X; Murphy TC; Nanes MS; Marcus R; Holloway L; Beamer WG; Rosen CJ
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4273-9. PubMed ID: 12213884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intermedin on proliferation, apoptosis and the expression of OPG/RANKL/M-CSF in the MC3T3-E1 osteoblast cell line.
    Ren H; Ren H; Li X; Yu D; Mu S; Chen Z; Fu Q
    Mol Med Rep; 2015 Nov; 12(5):6711-7. PubMed ID: 26398911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling?
    Van Bezooijen RL; Papapoulos SE; Löwik CW
    Bone; 2001 Apr; 28(4):378-86. PubMed ID: 11336918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts.
    Akune T; Ogata N; Hoshi K; Kubota N; Terauchi Y; Tobe K; Takagi H; Azuma Y; Kadowaki T; Nakamura K; Kawaguchi H
    J Cell Biol; 2002 Oct; 159(1):147-56. PubMed ID: 12379806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease.
    Stalvey MS; Clines KL; Havasi V; McKibbin CR; Dunn LK; Chung WJ; Clines GA
    PLoS One; 2013; 8(11):e80098. PubMed ID: 24236172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.